For the third quarter of the fiscal year ending December 2026, net sales were 42,422 thousand yen, a year-over-year decline. Operating loss was 834,147 thousand yen, ordinary loss was 835,701 thousand yen, and quarterly net loss was 910,077 thousand yen. Full-year earnings guidance has been revised and disclosed. Loss reduction progressed in the cell sheet regenerative medicine business, while the regenerative medicine support business saw decreased sales. Financial position improved as capital stock and capital surplus increased due to the exercise of stock acquisition rights, and cash and deposits increased, leading to a judgment that liquidity is stable.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7776","jir_company_name":"CellSeed Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/7776-20261113-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending December 2026, net sales were 42,422 thousand yen, a year-over-year decline. Operating loss was 834,147 thousand yen, ordinary loss was 835,701 thousand yen, and quarterly net loss was 910,077 thousand yen. Full-year earnings guidance has been revised and disclosed. Loss reduction progressed in the cell sheet regenerative medicine business, while the regenerative medicine support business saw decreased sales. Financial position improved as capital stock and capital surplus increased due to the exercise of stock acquisition rights, and cash and deposits increased, leading to a judgment that liquidity is stable.","jir_summary":"### Overview of Performance\nThis financial summary reports the financial results for the third quarter of the fiscal year ending December 2026. Net sales were 42,422 thousand yen (decrease Year-over-Year), operating loss was 834,147 thousand yen, ordinary loss was 835,701 thousand yen, and quarterly net loss was 910,077 thousand yen. By segment, the regenerative medicine support business recorded net sales of 37,944 thousand yen and an operating loss of 100,725 thousand yen, while the cell sheet regenerative medicine business recorded net sales of 4,477 thousand yen and an operating loss of 541,950 thousand yen, with deficits continuing in both segments. The full-year earnings guidance has been revised and disclosed. The exercise of the 25th series of stock acquisition rights has increased capital stock and capital surplus, indicating an improving capital structure; however, uncertainties remain regarding the company's ability to continue as a going concern.\n\n### Financial Position and Outlook\nTotal assets at the end of the third quarter were 1,819,030 thousand yen and net assets were 1,524,313 thousand yen, and an increase in cash and deposits led to a judgment that the financial base is stable. However, there remain uncertainties regarding early commercialization of the first regenerative medicine product, and future fundraising and partnership initiatives will be important. The financial summary notes that a revision to the earnings guidance for the fiscal year ending December 2026 has been disclosed, and results could change significantly depending on market conditions and R&D progress.","jir_financial_highlights":"Net Sales: 42,422 thousand yen (Year-over-Year -22,838 thousand yen)\nOperating Loss: -834,147 thousand yen (Increase of -9,556 thousand yen Year-over-Year)\nOrdinary Loss: -835,701 thousand yen (Increase of -11,904 thousand yen Year-over-Year)\nQuarterly Net Loss: -910,077 thousand yen (Increase of -60,565 thousand yen Year-over-Year)","jir_category":"","jir_hashtags":"#CellSeedEarnings, #FinancialInfo, #Q3, #RegenerativeMedicine","jir_key_figures":"Net Sales: 42,422 thousand yen (Year-over-Year -22,838 thousand yen)\nOperating Loss: -834,147 thousand yen (Year-over-Year -9,556 thousand yen)\nQuarterly Net Loss: -910,077 thousand yen (Year-over-Year -60,565 thousand yen)","jir_meta_title":"CellSeed Inc. Q3 FY2026 Financial Summary | Sales in the 42 million yen Range with Widening Losses","jir_meta_description":"Summary of CellSeed Inc.'s Q3 FY2026 financial results: net sales 42,422 thousand yen, operating loss 834,147 thousand yen, net loss 910,077 thousand yen. Explains the revised full-year guidance and key points for future business development.","jir_og_title":"CellSeed Inc. Announces Q3 Financial Results | Net Sales 42,422 thousand yen, Net Loss 910,077 thousand yen","jir_og_description":"Key points of CellSeed Inc.'s Q3 FY2026 results: sales and loss status related to regenerative medicine, progress on capital strengthening, and future business development.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59075,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-153371","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n